Grant: Idea to Innovation
University of Toronto
$14,996.00
Carboxyboronates: powerful building blocks for chemical synthesis
EF 2018-19
Résumé
Enabling the synthesis of novel chemical entities is critical to fueling drug discovery efforts. We have discovered carboxyboronate (CBA), a molecule that features a novel combination of two widely used functional groups-carboxylate and boronate-that has eluded chemical synthesis until now. CBA will serve as a novel drug discovery platform technology by enabling unique synthetic possibilities for the generation of novel small molecule drug candidates. This is because boron functionality has found widespread utility in cross-coupling reactions. In addition to offering a broadly applicable boron-based synthetic handle, boron-containing molecules (BCMs) derived from CBA are part of a larger class of small molecules called targeted covalent inhibitors (TCIs). TCIs have been experiencing a renaissance in modern drug discovery, having shown utility in multiple disease areas including cancer, bacterial infections, and fungal infections. Our technology overcomes these challenges to enable access to therapeutic agents whose assembly is based on the synthetic utility of the carbon-boron bond. In addition, this technology offers a way to generate large collections of potent and cell permeable BCMs, including carboxylate-containing BCMs such as CBA, which is poised to become a disruptive platform in the field of drug discovery.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
536388-2019
Name nom
Yudin, Andrei
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2019
Award amount
14996
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
Carboxyboronates: powerful building blocks for chemical synthesis
Keyword
NSERC
Application summary
Enabling the synthesis of novel chemical entities is critical to fueling drug discovery efforts. We have discovered carboxyboronate (CBA), a molecule that features a novel combination of two widely used functional groups-carboxylate and boronate-that has eluded chemical synthesis until now. CBA will serve as a novel drug discovery platform technology by enabling unique synthetic possibilities for the generation of novel small molecule drug candidates. This is because boron functionality has found widespread utility in cross-coupling reactions. In addition to offering a broadly applicable boron-based synthetic handle, boron-containing molecules (BCMs) derived from CBA are part of a larger class of small molecules called targeted covalent inhibitors (TCIs). TCIs have been experiencing a renaissance in modern drug discovery, having shown utility in multiple disease areas including cancer, bacterial infections, and fungal infections. Our technology overcomes these challenges to enable access to therapeutic agents whose assembly is based on the synthetic utility of the carbon-boron bond. In addition, this technology offers a way to generate large collections of potent and cell permeable BCMs, including carboxylate-containing BCMs such as CBA, which is poised to become a disruptive platform in the field of drug discovery.